A registrational trial of STRO-002 for patients with advanced ovarian cancer
Latest Information Update: 15 Nov 2022
At a glance
- Drugs Luveltamab tazevibulin (Primary)
- Indications Ovarian cancer
- Focus Registrational; Therapeutic Use
- Sponsors Sutro Biopharma
- 08 Nov 2022 According to a Sutro Biopharma media release, trial design will be presented by end of 2022.
- 13 May 2022 New trial record
- 09 May 2022 According to a Sutro Biopharma media release, Regulatory discussions for potential registrational trial planned planned for mid-year 2022.